A chronic challenge facing biologic drug discovery companies is the manufacturability of lead candidates. How do you ensure that the most promising hits from Discovery will make it through CMC development efforts? AbSci’s Protein Printing™ technology has revolutionized biomanufacturing and enabled production of high quality, complex therapeutic proteins in E. coli SoluPro®. Full-length antibody hit generation, affinity maturation, and cell line development can be performed within the Protein Printing™ platform, enabling simultaneous protein discovery and biomanufacturability objectives under accelerated timelines. Triage of high-performance hit and lead candidates due to biomanufacturing constraints is no longer necessary due to these breakthrough technologies.

Topics covered include:

• High-throughput cell line design technologies to enable rapid identification of novel proteins with high affinity antigen-binding and excellent manufacturability
• Novel assay technologies to enable high-throughput quantitative screening of biologic binding affinity and titer
• Cell line scalability and protein titer and quality metrics that meet pharma standards

This webinar will be targeted to senior technical staff and business development professionals in the pharmaceutical and biotech industries.